Primary Sjögren's syndrome (SS) is an autoimmune disorder affecting 0.2–3% of the general population (1). Its hallmark is chronic inflammation of the salivary and lacrimal glands, where lymphocytic infiltrates result in tissue destruction and cause loss of secretory function. Systemic manifestations are common, and B cell lymphoma occurs in nearly 5% of these patients (2–4). Pharmacologic treatments have the capacity to ameliorate the sicca symptoms, often transiently, but not to modify the course of the
